Roivant Sciences (ROIV) Non-Current Deffered Revenue (2022)
Roivant Sciences (ROIV) posted Non-Current Deffered Revenue of $11.9 million for Q3 2022, down 9.47% on a QoQ basis from $13.1 million in Q2 2022.
Roivant Sciences (ROIV) Non-Current Deffered Revenue (2022) Analysis & Trends
Roivant Sciences' Non-Current Deffered Revenue history runs 1 years deep, the most recent figure standing at $11.9 million for Q3 2022.
- Quarterly Non-Current Deffered Revenue changed N/A year-over-year to $11.9 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $11.9 million (changed N/A YoY) and the FY2022 annual result came in at $13.7 million, changed N/A from the prior year.
- Non-Current Deffered Revenue was $11.9 million for Q3 2022 at Roivant Sciences, down from $13.1 million in the prior quarter.
- Across five years, Non-Current Deffered Revenue topped out at $13.7 million in Q1 2022 and bottomed at $11.9 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Roivant Sciences | 24.35 Bn | 25.12 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 11.90 Mn |
| Jun 30, 2022 | 13.15 Mn |
| Mar 31, 2022 | 13.74 Mn |